[Ip-health] WHA69 - MSF intervention on Antimicrobial resistance

Joanna Keenan joanna.l.keenan at gmail.com
Fri May 27 08:56:25 PDT 2016

WHO 69th World Health Assembly: Agenda item 14.4 - Global Action Plan on
Antimicrobial Resistance
Speaker: Helle Aagaard

MSF witnesses antibiotic resistance in our programmes, including child
nutrition centres in Niger, burns units in Iraq and adult trauma centres in
Jordan and documented very resistant bacteria in our projects.

In recent years we have used last-line antibiotics for multi-drug resistant
gram-negative infections.
Multiple frameworks to tackle the systemic challenges causing and resulting
from AMR are emerging. While initiatives to make AMR a political priority
are helpful, they must be coordinated and not result in parallel or
conflicting processes. MSF urges WHO and Member States to ensure that the
needs of developing countries and vulnerable populations are not
forgotten; *instead
*they must be considered from the outset when priorities are set, products
designed, and access and stewardship strategies developed.

The UNHLM in September is an important opportunity to advance proposals and
to initiate negotiations for the necessary global frameworks, including one
for *development and stewardship*.

Looking towards the UNHLM, Member States should:

   - - Have in place resourced national action plans with accompanying
   surveillance data on the causes, prevalence and impacts of AMR
   - - Demand solutions for tools that are not fully utilised due to access
   barriers such as pneumococcal conjugate vaccines which can reduce
   antibiotic use by 47% for pneumonia cases but remain unaffordable for many
   - - Ensure priority setting for research and development is governed by
   WHO and Member States reflecting the health needs of all countries and
   commit to mandatory development of target product profiles to guide R&D of
   new diagnostics, vaccines, and treatments, which reflect the needs of all
   - - Aligning any global agreement on Development and Stewardship with
   the CEWG recommendations and principles, and the findings of the UNHLP on
   Access to Medicines, in order to ensure sustainable access, especially by
   delinking R&D costs from price and sales volume.

Joanna Keenan
Press Officer
Médecins Sans Frontières - Access Campaign
P: +41 22 849 87 45
M: +41 79 203 13 02
E: joanna.keenan[at]geneva.msf.org
T: @joanna_keenan


More information about the Ip-health mailing list